Plantibodies Market Size and Outlook 2030

Report Description

Forecast Period	2026-2030
Market Size (2024)	USD 60.91 Million
CAGR (2025-2030)	8.18%
Fastest Growing Segment	Tobacco
Largest Market	North America
Market Size (2030)	USD 97.63 Million

Market Overview

The Global Plantibodies Market , valued at USD 60.91 Million in 2024, is projected to experience a CAGR of 8.18% to reach USD 97.63 Million by 2030. Plantibodies are recombinant antibodies produced in genetically modified plants, designed for diverse therapeutic and diagnostic applications. The market's growth is predominantly supported by the intrinsic advantages of plant-based expression systems, notably lower production costs, superior scalability compared to conventional mammalian cell cultures, and a mitigated risk of contamination from human or animal pathogens. These systems also offer accelerated production timelines due to the rapid growth characteristics of host plants. According to The Good Food Institute, an organization supporting plant-based industries, companies primarily engaged in the broader plant molecular farming sector, which encompasses plantibodies, attracted investments totaling $37.8 million in 2023, an increase from $29.1 million in 2022.

This rising investment underscores confidence in the underlying technology. Nevertheless, a substantial challenge to market expansion remains the intricate and developing regulatory landscape for plant-derived pharmaceuticals, alongside potential public apprehension regarding genetically modified organisms used in therapeutic production.

Key Market Drivers

The Global Plantibodies Market is primarily driven by cost-effective production and scalability, along with a significantly reduced risk of pathogen contamination. Plant-based expression systems inherently bypass the high capital investments and operational costs associated with traditional mammalian cell cultures, which demand complex sterile bioreactor environments. This allows for scalable cultivation in diverse settings, enabling high-volume biopharmaceutical production at lower per-unit expenses. According to the National Science Foundation's Partnerships for Innovation Research Partnerships (PFI-RP) project, in its 2024 abstract, plant-based biomanufacturing platforms target production exceeding 500 mg per kilogram of plant fresh weight for functional human blood proteins, demonstrating substantial scalability. Furthermore, plantibodies offer an intrinsic safety advantage as plants do not host human or animal pathogens, eliminating potential adventitious agent transmission. The World Health Organization's (WHO) fact sheet on Antimicrobial Resistance, published in November 2023, noted bacterial antimicrobial resistance was directly responsible for 1.27 million global deaths in 2019, highlighting the critical importance of pathogen-free production.

These advantages are further enhanced by accelerated development timelines. According to a study cited in the journal Plants in February 2023, vaccine production using a transient expression system in *Nicotiana benthamiana* can be achieved within 8 weeks from obtaining the viral nucleotide sequence. This combination of efficiency, safety, and scalability positions plantibodies as a responsive and promising biopharmaceutical platform.

Download Free Sample Report

Key Market Challenges

The intricate and developing regulatory landscape for plant-derived pharmaceuticals poses a substantial impediment to the growth of the Global Plantibodies Market. The evolving nature of guidelines for genetically modified organisms used in therapeutic production creates uncertainty for developers and investors alike. This complexity often translates into extended timelines for product development and approval, delaying market entry for innovative plantibody candidates.

The compliance burden imposed by diverse and sometimes overlapping regulations significantly increases operational costs for companies engaged in plantibody manufacturing. According to the National Association of Manufacturers, the average manufacturer in the United States incurred over $29,000 per employee per year in federal regulatory compliance costs in 2022, measured in 2023 dollars. This substantial financial overhead, applicable across the manufacturing sector, directly impacts the economic viability of novel plant-based biopharmaceutical ventures. Furthermore, concerns voiced by industry stakeholders regarding cumbersome and lengthy regulatory processes for modified plants, as highlighted in a May 2024 joint regulatory plan by the Environmental Protection Agency, Food and Drug Administration, and United States Department of Agriculture, underscore the challenges in achieving predictable and efficient market pathways. These regulatory hurdles slow the translation of research into commercial products, consequently restricting overall market expansion.

Key Market Trends

The integration of artificial intelligence into plantibody discovery and optimization is accelerating development timelines and enhancing therapeutic precision. AI algorithms efficiently analyze extensive protein data, predicting optimal modifications for improved binding affinity and efficacy, thereby streamlining initial drug development phases. According to PhRMA, the biopharmaceutical industry invested nearly $101 billion in research and development in 2022, highlighting the sector’s robust commitment to innovation enabling advanced computational methods. For example, Stanford scientists developed a machine learning method achieving a 25-fold improvement in a SARS-CoV-2 antibody by predicting molecular changes, as reported in Science in July 2024. This showcases AI's direct influence on identifying highly effective plantibody variants.

The expanding regional footprint of biopharmaceutical manufacturing facilities is a critical trend for the plantibodies market, enhancing production capacity and supply chain resilience. This geographical diversification reduces risks associated with centralized production, bringing manufacturing closer to patient populations. PhRMA reported that the biopharmaceutical industry's total capital investment in U. S. plants and equipment exceeded $126 billion from 2018 to 2022, signifying continuous investment in manufacturing infrastructure. Illustrating this trend, AbbVie announced in April 2024 a $223 million expansion of its Singapore biologics manufacturing facility, adding 24,000 liters of drug-substance capacity. Such strategic investments in broader biologics production infrastructure cultivate favorable conditions for plantibody manufacturing across various global markets.

Segmental Insights

The tobacco segment is experiencing rapid growth within the Global Plantibodies Market, positioning it as the fastest-growing transgenic crop for antibody production. This accelerated expansion is primarily attributed to tobacco plants' well-established biotechnology infrastructure, which enables efficient genetic engineering and optimization for therapeutic antibody expression. Furthermore, tobacco offers a rapid growth cycle and high biomass yield, crucial factors that facilitate scalable and cost-effective production of plantibodies for clinical and commercial demands. Regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are also increasingly acknowledging plantibodies as a viable biopharmaceutical platform, further supporting the segment's development.

Regional Insights

North America emerges as the leading region in the global plantibodies market, driven by its well-established biotechnology and pharmaceutical industry. The region benefits from substantial investments in research and development, fostering a vibrant innovation ecosystem among academic institutions and corporate entities. A critical element is the supportive regulatory landscape, notably guided by the U. S. Food and Drug Administration (FDA) and Health Canada, which provides clear pathways for the development, approval, and commercialization of advanced biologic therapeutics, including plantibodies. This comprehensive framework, alongside the presence of prominent biopharmaceutical companies, significantly accelerates the translation of plantibody-based solutions to market.

Recent Developments

In July 2025, Healthgen Biotechnology, headquartered in Wuhan, secured marketing approval from the National Medical Products Administration in China for its recombinant human albumin, OsrHSA. This newly approved product, derived from rice and administered by injection, is indicated for treating hypoalbuminemia stemming from liver cirrhosis. This approval signifies a significant new product launch and a breakthrough in employing plant-based systems for the production of essential pharmaceutical proteins. Healthgen Biotechnology's achievement expands the utility of plant-derived biologics within the global plantibodies market, introducing a novel therapeutic option.

In April 2025, KBio Inc., a biotechnology company recognized for its involvement in biopharmaceutical research and development, announced the permanent closure of its Owensboro facility. This strategic decision will result in the cessation of operations impacting 46 employees across various departments, including plant biology and process development. The wind-down process was scheduled to begin on April 30, with the facility expected to cease all operations by late October 2025. This development signifies a notable change in the operational landscape for a company within the global plantibodies market.

In April 2025, PlantForm Corporation, in partnership with Baiya Phytopharm and The DABOM, launched a collaborative effort focused on the production of artificial plant-made exosomes. These exosomes are slated for application in therapeutics and advanced vaccine development. The collaboration utilizes PlantForm's proprietary plant-based manufacturing platform, known for its ability to produce high-value proteins and antibodies efficiently and cost-effectively. This initiative represents a breakthrough in research by combining specialized expertise to further plant-derived therapeutic solutions, addressing innovative delivery mechanisms within the global plantibodies market.

In March 2025, PlantForm Corporation initiated a collaboration with Smart Biotech to evaluate the plant-based production of antigens specifically for avian influenza diagnostic testing. This project leverages PlantForm's proprietary vivoXPRESS® system, a plant-based manufacturing technology, aiming to establish highly efficient and scalable methods for antigen production. The primary focus is on advancing animal health solutions, providing innovative tools for disease detection. This strategic alliance underscores ongoing research and development by companies in the global plantibodies market to broaden the application of plant-derived proteins, addressing crucial veterinary challenges.

Key Market Players

PlantForm Corporation
Planet Biotechnology Inc.
iBio, Inc.
Mapp Biopharmaceutical, Inc. (Allergan, Inc.)
Medicago Inc.
NOMAD Bioscience GmbH
Ventria Bioscience Inc.
Agrisera AB
Creative Biolabs, Inc.
Protalix BioTherapeutics Inc.

By Transgenic Crop	By Technique	By Application	By End User	By Region
Tobacco Legumes Cereals Seeds & Tubers Fruits & Vegetables Others	Conventional Method Tissue Culture Breeding & Sexual Crossing Transgenic Seeds Others	Autoimmune Diseases Cancer Infectious Diseases Immunization Dentistry Others	Biotechnology & Pharmaceutical Companies Academic & Research Institutes Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Plantibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Plantibodies Market , By Transgenic Crop:

o Tobacco

o Legumes

o Cereals

o Seeds & Tubers

o Fruits & Vegetables

o Others

Plantibodies Market , By Technique:

o Conventional Method

o Tissue Culture

o Breeding & Sexual Crossing

o Transgenic Seeds

o Others

Plantibodies Market , By Application:

o Autoimmune Diseases

o Cancer

o Infectious Diseases

o Immunization

o Dentistry

o Others

Plantibodies Market , By End User:

o Biotechnology & Pharmaceutical Companies

o Academic & Research Institutes

o Others

Plantibodies Market , By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Plantibodies Market .

Available Customizations:

Global Plantibodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Plantibodies Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Plantibodies Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Transgenic Crop (Tobacco, Legumes, Cereals, Seeds & Tubers, Fruits & Vegetables, Others)

5.2.2. By Technique (Conventional Method, Tissue Culture, Breeding & Sexual Crossing, Transgenic Seeds, Others)

5.2.3. By Application (Autoimmune Diseases, Cancer, Infectious Diseases, Immunization, Dentistry, Others)

5.2.4. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutes, Others)

5.2.5. By Region

5.2.6. By Company (2024)

5.3. Market Map

6. North America Plantibodies Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Transgenic Crop

6.2.2. By Technique

6.2.3. By Application

6.2.4. By End User

6.2.5. By Country

6.3. North America: Country Analysis

6.3.1. United States Plantibodies Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Transgenic Crop

6.3.1.2.2. By Technique

6.3.1.2.3. By Application

6.3.1.2.4. By End User

6.3.2. Canada Plantibodies Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Transgenic Crop

6.3.2.2.2. By Technique

6.3.2.2.3. By Application

6.3.2.2.4. By End User

6.3.3. Mexico Plantibodies Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Transgenic Crop

6.3.3.2.2. By Technique

6.3.3.2.3. By Application

6.3.3.2.4. By End User

7. Europe Plantibodies Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Transgenic Crop

7.2.2. By Technique

7.2.3. By Application

7.2.4. By End User

7.2.5. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Plantibodies Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Transgenic Crop

7.3.1.2.2. By Technique

7.3.1.2.3. By Application

7.3.1.2.4. By End User

7.3.2. France Plantibodies Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Transgenic Crop

7.3.2.2.2. By Technique

7.3.2.2.3. By Application

7.3.2.2.4. By End User

7.3.3. United Kingdom Plantibodies Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Transgenic Crop

7.3.3.2.2. By Technique

7.3.3.2.3. By Application

7.3.3.2.4. By End User

7.3.4. Italy Plantibodies Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Transgenic Crop

7.3.4.2.2. By Technique

7.3.4.2.3. By Application

7.3.4.2.4. By End User

7.3.5. Spain Plantibodies Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Transgenic Crop

7.3.5.2.2. By Technique

7.3.5.2.3. By Application

7.3.5.2.4. By End User

8. Asia Pacific Plantibodies Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Transgenic Crop

8.2.2. By Technique

8.2.3. By Application

8.2.4. By End User

8.2.5. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Plantibodies Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Transgenic Crop

8.3.1.2.2. By Technique

8.3.1.2.3. By Application

8.3.1.2.4. By End User

8.3.2. India Plantibodies Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Transgenic Crop

8.3.2.2.2. By Technique

8.3.2.2.3. By Application

8.3.2.2.4. By End User

8.3.3. Japan Plantibodies Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Transgenic Crop

8.3.3.2.2. By Technique

8.3.3.2.3. By Application

8.3.3.2.4. By End User

8.3.4. South Korea Plantibodies Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Transgenic Crop

8.3.4.2.2. By Technique

8.3.4.2.3. By Application

8.3.4.2.4. By End User

8.3.5. Australia Plantibodies Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Transgenic Crop

8.3.5.2.2. By Technique

8.3.5.2.3. By Application

8.3.5.2.4. By End User

9. Middle East & Africa Plantibodies Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Transgenic Crop

9.2.2. By Technique

9.2.3. By Application

9.2.4. By End User

9.2.5. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Plantibodies Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Transgenic Crop

9.3.1.2.2. By Technique

9.3.1.2.3. By Application

9.3.1.2.4. By End User

9.3.2. UAE Plantibodies Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Transgenic Crop

9.3.2.2.2. By Technique

9.3.2.2.3. By Application

9.3.2.2.4. By End User

9.3.3. South Africa Plantibodies Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Transgenic Crop

9.3.3.2.2. By Technique

9.3.3.2.3. By Application

9.3.3.2.4. By End User

10. South America Plantibodies Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Transgenic Crop

10.2.2. By Technique

10.2.3. By Application

10.2.4. By End User

10.2.5. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Plantibodies Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Transgenic Crop

10.3.1.2.2. By Technique

10.3.1.2.3. By Application

10.3.1.2.4. By End User

10.3.2. Colombia Plantibodies Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Transgenic Crop

10.3.2.2.2. By Technique

10.3.2.2.3. By Application

10.3.2.2.4. By End User

10.3.3. Argentina Plantibodies Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Transgenic Crop

10.3.3.2.2. By Technique

10.3.3.2.3. By Application

10.3.3.2.4. By End User

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Plantibodies Market : SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. PlantForm Corporation

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Planet Biotechnology Inc.

15.3. iBio, Inc.

15.4. Mapp Biopharmaceutical, Inc. (Allergan, Inc.)

15.5. Medicago Inc.

15.6. NOMAD Bioscience GmbH

15.7. Ventria Bioscience Inc.

15.8. Agrisera AB

15.9. Creative Biolabs, Inc.

15.10. Protalix BioTherapeutics Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Plantibodies Market in 2024?

Which is the dominating region in the Global Plantibodies Market ?

Which is the fastest growing segment in the Global Plantibodies Market ?

What is the expected growth rate of the Global Plantibodies Market ?